Fear Modulation of IL excitability
IL 兴奋性的恐惧调节
基本信息
- 批准号:8574536
- 负责人:
- 金额:$ 47.76万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2013
- 资助国家:美国
- 起止时间:2013-08-01 至 2017-07-31
- 项目状态:已结题
- 来源:
- 关键词:AffectAgonistAnimalsAuditoryBilateralBrainCellsDepressed moodDevelopmentDopamineDopamine ReceptorExtinction (Psychology)FrightFunctional ImagingGlucocorticoid ReceptorGoalsHippocampus (Brain)Infusion proceduresIon ChannelLeadMeasurementMeasuresMedialMediatingMemoryMental DepressionMuscimolN-Methyl-D-Aspartate ReceptorsN-MethylaspartateNeuronsPatientsPhobic anxiety disorderPost-Traumatic Stress DisordersPrefrontal CortexRattusResearchRoleSliceStructureTestingVoltage-Gated Potassium Channelbaseconditioned fearconditioningimprovedinhibitor/antagonistneuronal excitabilitynovelpatch clamppreventpublic health relevancereceptorresearch studyresponsevoltage
项目摘要
DESCRIPTION (provided by applicant): Functional imaging studies in PTSD patients suggest that reduced activation of the medial prefrontal cortex (mPFC) contributes to the excessive fear response seen in these patients. To understand why the mPFC is less activated in PTSD patients, we need to understand the mechanisms by which fear conditioning and extinction alter mPFC excitability. Patch-clamp recordings of infralimbic (IL) neurons in the mPFC revealed that the intrinsic excitability of IL neurons was depressed by fear conditioning in rats. The depressed IL excitability could reduce IL activation and enhance conditioned fear responses. Consistent with this, reducing IL intrinsic excitability enhances conditioned fear response. These findings imply that intrinsic plasticity in IL contributes to the consolidation of the conditioned fear memory. The goal of this proposal is to extend these results by examining the mechanisms and circuits involved in this fear conditioning-induced depression of IL intrinsic excitability. In Aim1, the role of NMDA receptors, D2-like dopamine receptors, and glucocorticoid receptors in the fear conditioning-induced depression of IL intrinsic excitability will be examined. In Aim 2, the role of hippocampal inputs in the fear conditioning-induced depression of IL excitability will be evaluated. In Aim 3, we will evaluate whether sustained voltage-gated K+ channels contribute to the fear conditioning-induced depression of IL excitability. A better understanding of the mechanisms leading to intrinsic plasticity in this brain structure may provide direction for the development of novel treatments for PTSD.
描述(由申请人提供):PTSD患者的功能成像研究表明,内侧前额叶皮层(mPFC)的激活减少导致这些患者出现过度恐惧反应。为了理解为什么mPFC在PTSD患者中激活较少,我们需要了解恐惧条件反射和消退改变mPFC兴奋性的机制。膜片钳记录显示,大鼠mPFC的边缘下(IL)神经元的内在兴奋性被恐惧条件反射抑制。抑制IL的兴奋性可降低IL的激活,增强条件性恐惧反应。与此一致,降低IL内在兴奋性增强条件性恐惧反应。这些结果表明,IL的内在可塑性有助于巩固的条件性恐惧记忆。这项建议的目标是通过研究这种恐惧条件反射诱导的IL内在兴奋性抑制的机制和电路来扩展这些结果。在Aim 1中,将检查NMDA受体、D2样多巴胺受体和糖皮质激素受体在恐惧条件反射诱导的IL内在兴奋性抑制中的作用。在目的2中,将评估海马输入在恐惧条件化诱导的IL兴奋性抑制中的作用。在目标3中,我们将评估持续的电压门控K+通道是否有助于恐惧条件反射诱导的IL兴奋性抑制。更好地理解导致这种大脑结构内在可塑性的机制可能为开发PTSD的新治疗方法提供方向。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
James T. Porter其他文献
James T. Porter的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('James T. Porter', 18)}}的其他基金
Technologies and Resources for Research Laboratories
研究实验室的技术和资源
- 批准号:
10417261 - 财政年份:2020
- 资助金额:
$ 47.76万 - 项目类别:
Technologies and Resources for Research Laboratories
研究实验室的技术和资源
- 批准号:
10654644 - 财政年份:2020
- 资助金额:
$ 47.76万 - 项目类别:
Technologies and Resources for Research Laboratories
研究实验室的技术和资源
- 批准号:
10027576 - 财政年份:2020
- 资助金额:
$ 47.76万 - 项目类别:
Technologies and Resources for Research Laboratories
研究实验室的技术和资源
- 批准号:
10252031 - 财政年份:2020
- 资助金额:
$ 47.76万 - 项目类别:
Effects of early-life neglect and cocaine use on PTSD-like behaviors
早期生活忽视和可卡因使用对 PTSD 样行为的影响
- 批准号:
10569007 - 财政年份:1997
- 资助金额:
$ 47.76万 - 项目类别:
Effects of early-life neglect and cocaine use on PTSD-like behaviors
早期生活忽视和可卡因使用对 PTSD 样行为的影响
- 批准号:
10343804 - 财政年份:1997
- 资助金额:
$ 47.76万 - 项目类别:
Thalamocortical Stimulation of Somotosensory Interneurons
丘脑皮质刺激体感中间神经元
- 批准号:
7629039 - 财政年份:
- 资助金额:
$ 47.76万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 47.76万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 47.76万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 47.76万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 47.76万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 47.76万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 47.76万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 47.76万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 47.76万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 47.76万 - 项目类别:
Fentanyl Addiction: Individual Differences, Neural Circuitry, and Treatment with a GLP-1 Receptor Agonist
芬太尼成瘾:个体差异、神经回路和 GLP-1 受体激动剂治疗
- 批准号:
10534864 - 财政年份:2023
- 资助金额:
$ 47.76万 - 项目类别:














{{item.name}}会员




